ArticleAge and ageing2025
Changes in anticholinergic cognitive burden and risk of single and recurrent falls: population-based cohort study.
Article in Age and ageing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and geriatric factors associated with fracture risk in older adults with bone metastases: A prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Anticholinergic burden in community-dwelling older adults: prevalence, associated factors, and agreement between measurement scales.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMedications with high anticholinergic cognitive burden (ACB) are associated with increased fall risk in older adults. However, the potential alteration of risk with changes in ACB over time has yet to be established.
objectiveTo estimate the association between the changes in ACB with single and recurrent falls.
methodsData from European Investigation of Cancer-Norfolk (EPIC-Norfolk) study participants, aged 40 years and above, who attended the first (1HC:1993-98), second (2HC:1998-2000) and third (3HC: 2004-11) health checks were utilised. The main outcome was a single fall event or recurrent ($\ge 2$) falls occurring during the 12 months preceding the time point of the 3HC.
resultsData from 10 717 participants with a median, Interquartile range (IQR) age of 55.6 (13.1) years were included. Three thousand four hundred forty-five (32.2%) participants had an ACB of one or greater at baseline. Participants were classified into four groups: no (67.8%), late (21.1%), transient (6.8%) and continuous (4.3%). Late (OR 1.49, 95% CI 1.25-1.79), transient (1.66, 1.28-2.14) and continuous (1.67, 1.22-2.29) exposure were significantly associated with increased recurrent falls compared with no exposure. Mediation analysis revealed that gait speed (GS) contributed to 16.9% (CI: 9.4%-27.8%) of the increase in risk of recurrent falls associated with ACB. DISCUSSION: Anticholinergic medication use, in adults aged 40 years and above, was linked to recurrent falls at 14-year follow-up, regardless of whether introduction or cessation occurred during the follow-up. Future research should determine effective strategies for minimising the long-term risk of falls when starting anticholinergic medications, which could include GS as a risk-detection and monitoring tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.